
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39223185
71316
10.1038/s41598-024-71316-3
Article
Cognitive subgroups of affective and non-affective psychosis show differences in medication and cortico-subcortical brain networks
Bracher Katharina M. 1
Wohlschlaeger Afra 2
Koch Kathrin 2
Knolle Franziska franziska.knolle@tum.de

2
1 grid.5252.0 0000 0004 1936 973X Division of Neurobiology, Faculty of Biology, LMU Munich, 82152 Martinsried, Germany
2 https://ror.org/02kkvpp62 grid.6936.a 0000 0001 2322 2966 Department of Diagnostic and Interventional Neuroradiology, School of Medicine, Technical University of Munich, Munich, Germany
2 9 2024
2 9 2024
2024
14 2031429 3 2024
27 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Cognitive deficits are prevalent in individuals with psychosis and are associated with neurobiological changes, potentially serving as an endophenotype for psychosis. Using the HCP-Early-Psychosis-dataset (n = 226), we aimed to investigate cognitive subtypes (deficit/intermediate/spared) through data-driven clustering in affective (AP) and non-affective psychosis patients (NAP) and controls (HC). We explored differences between three clusters in symptoms, cognition, medication, and grey matter volume. Applying principal component analysis, we selected features for clustering. Features that explained most variance were scores for intelligence, verbal recognition and comprehension, auditory attention, working memory, reasoning and executive functioning. Fuzzy K-Means clustering on those features revealed that the subgroups significantly varied in cognitive impairment, clinical symptoms, and, importantly, also in medication and grey matter volume in fronto-parietal and subcortical networks. The spared cluster (86%HC, 37%AP, 17%NAP) exhibited unimpaired cognition, lowest symptoms/medication, and grey matter comparable to controls. The deficit cluster (4%HC, 10%AP, 47%NAP) had impairments across all domains, highest symptoms scores/medication dosage, and pronounced grey matter alterations. The intermediate deficit cluster (11%HC, 54%AP, 36%NAP) showed fewer deficits than the second cluster, but similar symptoms/medication/grey matter to the spared cluster. Controlling for medication, cognitive scores correlated with grey matter changes and negative symptoms across all patients. Our findings generally emphasize the interplay between cognition, brain structure, symptoms, and medication in AP and NAP, and specifically suggest a possible mediating role of cognition, highlighting the potential of screening cognitive changes to aid tailoring treatments and interventions.

Subject terms

Computational neuroscience
Diagnostic markers
Technische Universität München (1025)Open Access funding enabled and organized by Projekt DEAL.

issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Cognitive alterations are core symptoms of psychosis1–4, which have been described in areas of working memory5,6, attention7,8, reasoning9,10, decision-making11–13, salience processing14,15, learning (e.g., lower learning rate or increased forgetting,16–18) and problem solving19,20 and across all stages of the disease21–25. Cognitive deficits furthermore precede the clinical onset of psychosis26, and predict functional outcome in later stages of the disease27,28, impacting employment status, independent living and social functioning28,29. Although cognitive impairments are present in about 80% of patients suffering from psychotic disorders30–32, therapeutic interventions are limited. A meta-analysis including 93 studies using different agents targeting mainly glutamatergic and cholinergic neurotransmitter systems, but also serotonin, dopamine, GABA and noradrenaline agents33 reported a significant, although very small (g = 0.10) improvement of cognition in general. However, this meta-analysis failed to find significant improvement for cognitive subdomains33. Cognitive training, also called cognitive remediation therapy, has produced more promising effects34,35. A recent meta-analysis found that cognitive remediation showed significant small-to-moderate cognitive improvements in all domains studied (g = .19–.33) and a small improvement in function (g = .21). Furthermore, research has shown that fewer cognitive deficits and higher cognitive reserve during prodromal and first episode psychosis are generally, independent of diagnosis, associated with better functioning and recovery36,37. This indicates that maintaining and improving cognitive functioning is crucial in the interventional and therapeutic processes.

Cognitive deficits in psychosis, in general, have been linked to alterations in the cortico-cerebellar-thalamic-cortical circuits38. Here, dysfunctional GABA (gamma-amino-butyric acid) inter-neurons, the main inhibitory neurons of the central nervous system, may disrupt the balance between excitatory and inhibitory processes in the cortex39. A recent review25 summarizes the association between functional brain alterations and cognitive deficits in individuals at-risk for psychosis, early onset psychosis, and chronic schizophrenia. They report a clear association between altered cortical (e.g., prefrontal cortex, anterior cingulate cortex, insula) and subcortical (e.g., thalamus, striatum, hippocampus, cerebellum) brain signalling and aberrant cognition across the different stages. Imaging studies provide further support showing reduced grey matter volume and altered network organization which correlates with cognitive deficits at illness onset40,41, early psychosis42 and chronic schizophrenia43. Furthermore, a study by Van Rheenen et al.44 reported global grey matter volume and thickness reductions which were more prominent in patients with stronger cognitive impairments.

Interestingly, psychosis patients with different diagnoses, e.g., affective vs non-affective psychosis, show varying cognitive deficits45–47. In a review, Barch and Sheffield47 summarized that while the severity of cognitive impairment is stronger in non-affective compared to affective psychosis, the relative impairments across different cognitive domains are very similar. Other studies, however, do not differentiate between affective vs non-affective psychosis when investigating cognitive deficits34,48,49. Despite these differences in cognitive alterations with regard to specific diagnoses, cognitive deficits in psychosis have been described and investigated as intermediate phenotypes50. In a recent study, Shafee et al.51 revealed that cognitive phenotypes may vary grossly depending on specific types of psychosis (e.g. affective vs non-affective), suggesting that certain domains of cognition (e.g., working memory vs face processing) may be more etiologically linked to psychosis than others. Using a K-means clustering approach in a cross-diagnostic sample, Lewandowski et al.52 identified four cognitive subgroups combining different psychosis groups. Importantly, they identified one cognitively intact cluster consisting of healthy controls and patients with different diagnoses, while the other three clusters were dominated by different cognitive impairment profiles52. The data-driven identification of cognitive clusters varies between two and four-cluster solutions, as shown in a recent systematic review53. One major contributing factor may be the variance in the data, especially the cognitive measures that are being used. Interestingly, a recent systematic review of data-driven identification of cognitive subtypes54 highlighted that despite the heterogeneity of clustering methods used and cognitive domains studied, there is some commonality in the identification of a severe cognitive deficit phenotype showing deficits across multiple domains, and a spared cognitive deficit phenotype with similar performances to controls. While it is unclear from the literature which cluster solution is the most reliable, especially an intermediate phenotype may be interesting from an interventional point of view, as this group of individuals may benefit the most from cognitive interventions to improve functional outcome. It has been shown55 that patients at early compared to late illness stages have a higher potential for cognitive improvement after cognitive remediation therapy. This may be directly translatable to an intermediate cognitive phenotype, as this group may possess residual cognitive abilities that can be enhanced through targeted interventions and may also have more intact neural substrates that support cognitive training. Furthermore, those cognitive improvements may be more likely to translate into functional gains, such as better social and occupational outcomes, which are crucial for improving the overall quality of life56–58. Additionally, all studies using cognitive clustering concentrated on cognitive toolboxes, or basic measures such as measures of processing speed or working memory. Using simple task data, however, such as the Delay Discounting task may be a beneficial contribution as they include reward processing an ability reported to be impaired across all stages of psychosis12,13,15,17. Furthermore, it is unclear how cognitive subtypes are linked to differences in medication status and brain structure (i.e., grey matter volume). These open questions, however, are crucial to understand whether cognitive subtypes are clinically relevant, and whether they could increase our mechanistic understanding of the disorder.

In the current study, we, therefore, aimed to explore these important questions. First, we wished to investigate three cognitive subtypes using the HCP Early Psychosis dataset (https://www.humanconnectome.org/study/human-connectome-project-for-early-psychosis,59) using data-driven clustering on standardized cognitive, perceptual and emotional task and score data, but no clinical data. Second, we explored whether the patients in the three clusters differed in symptom expression, cognition, medication and grey matter volume. And third, depending on the results for the first two questions, we wished to understand if symptoms, alterations in cognition and brain morphometry were linked while controlling for medication within and across the clusters.

Methods

Participants

We analyzed data collected by the “Human Connectome Project for Early Psychosis” (HCP-EP,49,60). The HCP-EP 1.1 release (August 2021 HCP-EP Release 1.1 on NDA) contains 251 subjects consisting of 68 healthy control individuals, 57 patients with affective and 126 patients with non-affective psychosis, both patient groups were within the first three years of the onset of psychotic symptoms. The Structured Clinical Interview for DSM-5: Research Version (SCID-5-RV)61 was used to confirm diagnoses of non-affective (i.e., schizophrenia, schizophreniform, schizoaffective, psychosis not otherwise specified, delusional disorder, brief psychotic disorder) or affective psychosis (i.e., major depression with psychosis or bipolar disorder with psychosis). Clinical symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS,62). Disease onset for all patients was within the last five years prior to study enrollment. For a comprehensive cognitive, perceptual and emotional assessment, the NIH toolbox (63,64; i.e., cognition (Picture Sequence test, Dimensional Change test, Flanker test, Picture Vocabulary test, Pattern Completion test, List Scoring test, and Oral Reading test), emotion (Self-report emotion), perception (Words in Noise, Odor Identification, and Dynamic Visual Acuity), sensory-motor functions (9-Hole Pegboard, and Grip Strength), the HCP Lifespan Measures (65; i.e., Delay Discounting and Penn Emotion Recognition), the WASI-II66 and the Seidman Auditory Continuous Performance Test67 was used. Structural brain imaging data was available for 183 of the 251 subjects. After ensuring that there were sufficient data for features and subjects (see description of analysis below), the analysis was performed on 226 subjects (i.e., 56 healthy controls, 52 affective psychosis group, 118 non-affective psychosis group). Demographics and clinical scores for the three groups are presented in Tab. 1. Detailed analysis of PANSS items are presented in Suppl. Fig. S1.

Ethics statement

All participants provided written informed consent to participate in the HCP-EP, and for their data to be shared openly. HCP-EP was reviewed and approved by the Human Connectome Project (HCP). The HCP-EP complied with the ethical standards of the relevant national and institutional committees on human experimentation and with the code of ethics of the World Medical Association, the Helsinki Declaration of 1975, as revised in 2013.Table 1 Group demographics and clinical scores of final sample (N = 226).

	Control	Affective	Non-Affective	Group comparison KW-chi2/P-ch2, chi2(df), p-value	
N	56	52	118		
Age—mean (std)	24.55 (4.42)	23.63 (3.85)	22.73 (3.38)	7.25 (2), <0.05	
Gender—female %	33.9	57.7	30.51	11.78 (2), <0.01	
PANSS total	Na	45.3 (12.87)	51.97 (14.54)	14.71 (1), <0.001	
PANSS positiv	Na	10.1 (3.89)	12.17 (4.59)	9.09 (1), <0.01	
PANSS negative	Na	11.65 (4.66)	14.14 (5.58)	9.44 (1), <0.01	
General psycho-pathology	Na	23.52 (6.22)	25.67 (5.69)	7.01 (1), <0.01	

Variable selection and preprocessing

Initially, all cognitive, perceptual and social/emotional functioning scores available in the HCP-EP dataset were selected, resulting in 70 variables as potentially relevant to our analysis (Suppl. Table S1). As covariates, we chose age, gender, socio-economic status and mother’s level of education. Variables containing information of primary diagnosis for affective and non-affective psychosis, such as the PANSS or the Clinical Assessment Interview for Negative Symptoms, as well as variables describing medication dosage, usage or equivalent doses, were not included in the clustering analysis, but only used for subsequent analyses.

Many of the selected variables contained missing data. We therefore excluded variables when more than 10% of the entries were missing, and we excluded subjects with more than 20% missing variables (Suppl. Table S1). As a result, 33 out of the initial 70 variables remained in the data set and 226 subjects. The distribution of the remaining subjects reflected the distribution of the original data with regard to diagnosis type. For an overview of selected variables and group comparison, see Suppl. Table S2. In the final dataset used for analysis, subjects were missing a maximum of seven variables (Suppl. Table S3 and S4). Missing data were imputed using the mean for continuous and mode for categorical variables (e.g. demographic control variables). Since the ratio of patients and controls was not balanced, mean or mode for data imputation was calculated separately for patients and controls. Both patient groups were combined in order to minimize the bias of classical group membership (Suppl. Table S2).

Prior to our analysis, all continuous features and covariates were normalized using z-score normalization. Ordinal covariates such as socio-economic status and mother’s education were scaled between 0 and 1, and gender was treated as a binary variable.

In (Fuzzy) K-Means clustering, all input features are considered equally, and no feature selection is inherently performed. Therefore, it is crucial to carefully choose which features to include, as each will impact the clustering results. To address this, we used principal component analysis (PCA) as a further preprocessing step. PCA helps reduce the dimensionality of the data, retaining only the most significant components based on how much variance is being explained. This is an essential preprocessing step to improve the clustering performance. PCA is suitable for our data type68,69, and was applied to all variables. Covariates were also included as control variables, which at the same time allowed us to detect whether any covariate might be influential. Significant principal components were identified using a permutation test (5000 random permutations of each feature across subjects). Components that survived permutation testing were considered significant.

The HCP-EP brain imaging data contained structural magnetic resonance imaging (MRI) data. We used T1-weighted structural images recorded at a 3T SIEMENS MAGNETOM Prisma scanner using an MPRAGE sequence (TR = 2400ms, TE = 2.22ms, FoV read = 256mm, FoV phase = 93.8%, flip angle = 8 deg, slices per slap = 208, slice thickness = 0.8mm). In order to receive individual grey matter volume for structural covariance networks generated across all subjects (Suppl. Fig. S2), the structural brain data was preprocessed as described in the supplementary material A.4 and elsewhere70. In short, structural covariance network analyses apply an independent component analysis which is based on all subjects’ grey matter maps in order to identify common spatial components. These components are derived from the covariation of grey matter patterns across all participants. We allowed the process to identify 30 components (i.e., structural covariance networks, SCN), as done previously70–72. While atlas-based procedures are usually based on brain segmentations derived from healthy brains, the procedure of the present study has the advantage of taking the brain anatomy of both healthy individuals as well as patients into account, thus avoiding a healthy brain bias of other methods. Differences within these group-independent networks identified by the current method should therefore be highly reliable, and the risk of false positive results should be minimized. The structural covariance networks were used for analyses following the clustering.

Correlation and homogeneity

To investigate correlations between all features, we performed a Pearson’s correlation between all subjects’ non-standardized variables. Differences in correlations between the groups were evaluated with a T-test for means of two independent samples. We then tested homogeneity between groups, using Levene’s test for equal variances between groups. Bonferroni corrections were applied.

Fuzzy clustering

Instead of a hard clustering approach that assumes well separated clusters and assigns each data point to only one cluster (e.g., K-Means), we used a soft clustering approach. This approach accounts for fuzzy boundaries between groups, and is thus better suited for overlapping subgroups73, as would be expected for clinical groups. We, therefore, used Fuzzy K-Means clustering as described in Bezdek et al74. As input to our clustering analysis, we used the dimensionality-reduced data which included demographic control variables for all three groups (i.e., controls, affective and non-affective patients). We specified the number of clusters prior to our analysis. We used a priori knowledge about the number of cognitive clusters (i.e., three different cognitive clusters were reported in the literature54). As a control analysis, we also used three clusters on the patient data only. This analysis was used to determine influence of control subjects on the clustering, and is presented in the supplements (Suppl. Fig. S4). Although we used a predefined number of clusters, which was based on other studies54, a data-driven approach supports this view at least partially, showing that three clusters could also be derived from the investigation of inertia (Suppl. Fig. S5). The numbers of clusters should be chosen to achieve low inertia and a low number of clusters. Commonly, the elbow method is employed, which identifies the point after which the improvement in the inertia value levels off. With this method, we identified three clusters the best solution (Suppl. Fig. S5a). However, other partition indices, such as the partition coefficient (Suppl. Fig. S5b) and the partition entropy coefficient (Suppl. Fig. S5c), which are often chosen for fuzzy clustering75, indicated a two cluster solution as the preferable one as compared to a three or four cluster solution. A larger partition coefficient indicates low overlap between the clusters, meaning better separation, and a larger value of partition entropy coefficient, however, indicates a higher overlap between cluster. As no clear statement can be made from this data-driven point of view, we decided to follow the approach that allowed addressing our research question most appropriately, using a predefined number of three clusters.

Performance of the clustering analysis was determined by the ratio of the subjects of one group (healthy controls, affective psychosis group and non-affective psychosis group) in each cluster. The ratio of subjects in cluster j for group i in {controls, affective and non-affective} is defined as:ratioi,j=number of subjects of group i in cluster jtotal number of subjects of group i

Cluster exploration

After the identification of the three clusters, we explored differences in the patients distributed over those three clusters and controls in cognitive scores, clinical scores, medication and grey matter volume. The control subjects were removed from each of the clusters and combined in one healthy group. Thus, a group comparison across four groups was computed. For comparing groups, we used SciPy’s Kruskal-Wallis test with Dunn’s test for post-hoc analyses, a Chi-square test of independence or ranked analysis of variance (ANOVA) with Bonferroni corrected post-hoc tests. The Kruskal-Wallis test and Dunn’s test for post-hoc analyses are non-parametric, rank-based methods that minimize the impact of outliers by converting data into ranks. This approach reduces the influence of extreme values, as outliers are represented by extreme ranks rather than affecting the analysis based on their raw values. Consequently, both tests offer robust results even in the presence of outliers, ensuring that the outcomes are not disproportionately influenced by these extreme data points. As a control analysis, we performed partial Pearson’s correlations between cognitive scores, clinical scores, and grey matter volume controlled for medication across all patients, with multiple comparison corrections.

Statistical implementation

Preprocessing and data analysis was performed in Python 3.9.7. We used scikit-learn 1.0.2, SciPy 1.7.2 for all analyses and the fuzzy clustering implementation of Dias et al.76. Partial correlations were performed using the ppcor 1.177. For clustering analyses, brain data was corrected for total intracranial volume (TIV), age and sex, using the R stats package, version 4.0.5 R78.

Results

Homogeneity of data across groups

Correlations of all cognitive, perceptual and emotional functioning data revealed that correlations were highest within controls compared to affective (T-test: t5838=16.34, p<0.001) and non-affective (T-test: t17058=26.03, p<0.001) patients. For non-affective patients, correlations within subjects were lowest (non-affective vs. affective patients: T-test: t16626=8.47, p<0.001), indicating greatest variability. Confirming these results, highest heterogeneity was found in non-affective patients compared to controls (Levene’s test for equal variance: F1,174 = 187.3, p<0.001) and affective patients (Levene’s: F1,168 = 70.39, p<0.001). Controls were the most homogeneous (Levene’s: F1,106 = 22.34, p<0.001) (Fig. 1a).Figure 1 Variable correlations and dimensionality reduction of cognitive data. (a) All variables (i.e., cognitive, emotional, perceptual data) correlated across subjects using Pearson correlation. Correlations within groups are displayed in squares on the diagonal, and correlations between groups are displayed in off-diagonal squares. (b) Variance explained by each of the principal components (PCs) in % of a PCA performed on all variables and covariates across 226 subjects. The first five PCs (blue) survived permutation testing (p<0.05, 5000 permutations). Significant components captured 55.8 % of all variance. (c) Individual data points represent relevant variables for each subject, displayed on the first two principal components and are colored according to subject group affiliation.

Feature selection using principal component analysis

During the data dimensionality reduction, we identified five significant PCs using all data from all groups, which captured 55.8 % of the total variance (Fig. 1b). Explained variance of PCAs was consistent with other symptom-reduction studies79. Figure 1c illustrates the data reduction using the first two principal components. The two patient groups and the control group are predominantly distributed across the dimension of PC1. However, no clear boundaries between groups could be detected. The features that explained most variance were Fluid Intelligence and Crystallized Intelligence, Total IQ, the Picture Vocabulary Test, Oral reading recognition, Auditory attention, Working memory, WASI - Verbal comprehension, WASI - Matrix reasoning as well as DCCS - Executive functioning (Suppl. Fig. S3). To check the influence of combining patient and control data, the same analysis was performed on only patients data (without controls), which also resulted in five significant components that captured 53.7 % of all variance (p<0.05, 5000 permutations) (Suppl. Fig. S4a, b). The top ten features contributing to the explained variance were the same across both analysis—with and without controls. These features were taken for subsequent statistical analyses.

Group representation in the three clusters

We performed clustering on the significant PCs, including controls and both patient groups, with three clusters. Figure 2a and b present the results. One cluster (cluster 0) contained 86% (48/56) of all controls and 37% (19/52) of all affective subjects. Non-affective subjects were represented only in a small proportion of 17% (20/118). A mixed, second cluster (cluster 1) consisted of mostly patients, with the majority of affective individuals: 54% (28/52) of non-affective and 36% (42/118) of affective patients and only 11% (6/56) controls. Most non-affective subjects were contained in the third cluster (cluster 2) with 47% (56/118) of the non-affective, and only 10% of affective patients (5/52) and 4% (2/56) of controls. (Fig. 2b).Figure 2 Cluster analysis: group representations and cognitive differences. (a) Result of clustering. Cluster affiliation of each subject is displayed on the first two PCs. Colors correspond to cluster 0, 1 or 2. (b) Percentage of subjects of each group in each cluster. E.g. 47 % (56/118) of all non-affective subjects are in cluster 2.

Exploring cognition, symptoms, medication and grey matter volume in the clusters

To identify possible cognitive subgroups represented in the clusters, we explored cognitive scores and symptom expression for patients assigned to the clusters (see comprehensive display of statistical differences between all clusters and cognitive items in Suppl. Table S5). We compared cognitive scores across patients in respective clusters. Scores of control subjects were used for comparison. Patients in cluster 2 (mainly non-affective patients) showed a significant decrease in all cognitive features compared to patients assigned to other clusters as well as controls. Patients in cluster 1, which contains 28 affective and 42 non-affective patients, showed significant decrease of Fluid Cognition, Auditory attention (%correct) and DCCS - Executive functioning compared to controls. Patients (19 affective and 20 non-affective) in cluster 0 showed most similar scores compared to control subjects, with Auditory attention (%correct) being the only score that was significantly lower compared to controls (Fig. 3c). Group comparisons are presented in Table 2.

Patients in cluster 2, who showed the strongest cognitive deficits and who were mainly diagnosed with non-affective psychosis, showed a significantly increased PANSS total score compared to patients in both, cluster 0 and 1. They also had a significantly increased PANSS positive, PANSS negative score and general psychopathology compared to patients in cluster 0. Even though patients in cluster 0 and cluster 1 did not show as a strong difference in cognitive scores, patients in cluster 1 had a significantly increased PANSS total score and general psychopathology compared to patients in cluster 0 (Fig. 3a). Group comparisons are presented in Table 2.

Further, we explored the medication status of patients within the clusters. We found that patients assigned to cluster 2 had a significantly higher Chlorpromazine equivalence dose in general and at the scanning date compared to patients in both cluster 0 and 1, and a significant increase in lifetime antipsychotic drug exposure compared to patients in cluster 1 (Fig. 3b) and group comparisons are presented in Table 2.Figure 3 Symptom expression and medication status. (a) Clinical scores of affective and non-affective patients within each cluster are displayed in boxplots. Individual boxplots show data minimum, first quartile, median, third quartile, and data maximum. Individual subjects are overlaid as dots. Outliers are indicated outside the data minimum or maximum. (b) Medication dosage and status of affective and non-affective patients within each cluster. (c) Cognitive scores of affective and non-affective patients within each cluster are displayed and compared to all control subjects (c, light blue). The plots display the ten features contributing most to explained variance of the PCs. (d) Differences in three grey matter volume networks between affective and non-affective patients within each cluster are displayed and compared to all control subjects (c, light blue). NW 18 comprises the putamen and the amygdala; NW 29 comprises the paracingulate gyrus, the juxtapositional lobule, the superior parietal lobule, and the precentral gyrus; and the NW 30 comprises the superior frontal gyrus, the frontal pole, the putamen, the postcentral gyrus and the cerebellum crus. The plots display the ten features contributing most to explained variance of the PCs. Significance is indicated as p≤0.05 (*), p≤0.01 (**) and p≤0.001 (***).

We also considered differences in grey matter networks across the patients in the clusters and the controls. The ranked ANOVA revealed a highly significant interaction effect (F(87) = 2.564, p = 1.79e-13) between the patients in the three clusters and the controls (four groups) and the grey matter volume in each network (30 networks). Bonferroni corrected post-hoc analyses revealed significant differences in network 18 comprising the putamen and the amygdala (F(3,48.64) = 9.32, p = 0.00027), network 29 consisting of the paracingulate gyrus, the juxtapositional lobule, the superior parietal lobule, and the precentral gyrus (F(3,45.13) = 7.8, p = 6e-05) and network 30 including the superior frontal gyrus, the frontal pole, the putamen, the postcentral gyrus and the cerebellum crus (F(3,45) = 10.95, p = 2e-05) (Fig. 3d). Group comparisons are presented in Table 2.

Finally, we investigated partial Pearson correlations between the ten cognitive features, the three significant grey matter volume networks, and the clinical scores, controlling for Chlorpromazine equivalent dose within each cluster and across all patients. Across all patients, but not within the clusters, we found several significant, multiple-comparison-corrected associations, see Fig. 4 and Suppl. Table S6.Figure 4 Partial correlations between brain, cognition and clinical scores. Correcting for the equivalent dose of medication, we used Partial Pearson correlations to investigate the interaction between cognitive scores (i.e., Fluid Intelligence and Crystallized Intelligence, Total IQ, the Picture Vocabulary Test, Oral reading recognition, Auditory attention, Working memory, WASI - Verbal comprehension, WASI - Matrix reasoning as well as DCCS - Executive functioning), brain networks (i.e., NW18, NW29, NW30), and clinical scores (i.e., PANSS total, PANSS positive, PANSS negative, General psychopathology score) across all patients independent of cluster.

Table 2 Comparison between patients in all clusters and control subjects for cognitive features that contributed most to variance, as well as medication and PANSS comparison between patients in different clusters

Feature	Group comparison	Cluster 0–1	Cluster 0–2	Cluster 0–controls	Cluster 1–2	Cluster 1–controls	Cluster 2–controls	
Cognitive scores	
Fluid cognition	87.649, <0.001	ns	44.3611, <0.001	ns	40.0851, <0.001	15.5651, <0.001	64.5597, <0.001	
Crystallized cognition	112.1136, <0.001	ns	63.2746, <0.001	ns	84.5395, ns	ns	66.9227, <0.001	
Total IQ	108.7698, <0.001	ns	57.5106, <0.001	ns	74.8416, <0.001	ns	73.4878, <0.001	
Picture vocabulary test	101.079, <0.001	ns	57.5472, <0.001	ns	77.0475, <0.001	ns	59.3365, <0.001	
Oral reading recognition	92.0641, <0.001	ns	47.5712, <0.001	ns	68.125, <0.001	ns	59.9688, <0.001	
Auditory attention %correct	74.1838, <0.001	ns	31.6126, <0.001	11.0381, <0.01	33.1923, <0.001	12.2936, <0.01	57.8224, <0.001	
Working memory	71.9626, <0.001	ns	32.4261, <0.001	ns	51.8415, <0.001	ns	50.0042, <0.001	
WASI - Verbal comprehension	94.1753, <0.001	ns	51.1362, <0.001	ns	68.2115, <0.001	ns	60.9508, <0.001	
WASI - Matrix reasoning	69.0919, <0.001	ns	32.4274, <0.001	ns	38.7849, <0.001	6.9518, <0.05	51.9111, <0.001	
DCCS - Executive functioning	54.7055, <0.001	ns	27.6009, <0.001	ns	27.3806, <0.001	5.8383, <0.05	42.6152, <0.001	
Medication status	
Lifetime Antipsychotic Drug Exposure (months)	7.2749, <0.05	ns	ns		7.2484, <0.01			
Chlorpromazine Equivalence (mg/d)	29.132, <0.001	ns	12.5926, <0.001		25.8164, <0.001			
Scan Date Chlorpromazine Equivalence (mg)	25.9395,<0.001	ns	12.1334, <0.001		22.0764, <0.001			
Positive and negative symptom score	
PANSS total	38.0513, <0.001	13.3467, <0.0001	35.5926, <0.001		10.8473, <0.01			
PANSS positive	8.0705, <0.05	ns	8.37, <0.01		ns			
PANSS negative	36.7939, <0.001	ns	28.9601, <0.001		23.4758, <0.001			
General psychopathology	28.9654, <0.001	19.2588, <0.001	27.3522, <0.001		ns			
Brain clusters	
NW 18	23.0278, <0.001	ns	7.1728, <0.05	ns	15.5068, <0.001	ns	17.3921, <0.001	
NW 29	24.305, <0.001	ns	11.0358, <0.01	ns	15.5068, <0.001	ns	17.9004, <0.001	
NW 30	30.4236, <0.001	ns	15.1209, <0.001	ns	17.7453, <0.001	ns	22.9485, <0.001	
For the group comparison, a Kruskal-Wallis was used with a Dunn’s test for pairwise comparisons (statistics and p-value displayed or ns - non significant).

Discussion

The aim of this study was, first, to investigate three cognitive subtypes using the HCP Early Psychosis dataset using data-driven clustering on standardized cognitive, perceptual and emotional task and score data, but no clinical data; second, whether the patients in the three clusters differed in symptom expression, cognition, medication and grey matter volume; and, third, depending on the results for the first two aims, we wished to understand if symptoms, alterations in cognition and brain morphometry were associated when controlling for medication within and across the clusters. Using a data driven parameter selection and clustering approach, we were able to show significant differences across our three clusters revealing a cognitively intact cluster, an intermediately affected cluster and a cognitively affected cluster, which seem to confirm subgroups previously described in the literature36,52,80–85. Importantly, our results extend those findings, showing that patients within those clusters also differ in medication dosage in specific grey matter brain networks and in clinical symptoms. Interestingly, across all patients but not within clusters, we found that decreased grey matter volume in frontal, parietal and subcortical regions was linked to higher cognitive scores including crystallized cognition, verbal comprehension and matrix reasoning, when controlling for medication, and that decreased cognitive scores were linked to increased negative symptoms, when controlled for medication.

Using a three cluster solution on all participants (i.e., controls, affective and non-affective psychosis) allowed the identification of cognitive subtypes, which significantly varied in clinical and cognitive impairment. Patients of cluster 2, consisting of nearly 50% of the non-affective psychosis individuals, expressed the highest symptom scores across PANSS total, PANSS negative and positive and general psychopathology. They also showed impaired cognition in all domains compared to cluster 0 containing 17% of the non-affective and 37% of the affective individuals, and partially also compared to cluster 1 which consists of the majority of affective individuals and 36% of non-affective individuals. Patients in cluster 0 had the lowest symptom scores and globally spared cognitive abilities, which were similar to those of controls. Cluster 1 was intermediate, with cognitive impairments in several but not all domains and slightly increased symptoms compared to the cognitively spared cluster. This finding confirms results from Lewandowski et al.52 who found a four-cluster solution to provide the best fit to their data containing three diagnostic patient groups, with one globally impaired cluster for which cognitive deficits were associated with symptom severity and poorer functioning, one cognitively spared cluster and two intermediate clusters52. The overall structure of cognitive clusters identified in the present study supports findings discussed in a recent meta-analysis of data-driven identification of cognitive phenotypes in schizophrenia54. Green et al.54 describe that what is characteristic to all cluster solutions is the presence of a cognitively spared, one or multiple intermediate and a deficit subgroup54. Importantly, the current study explores three cognitive clusters using standard cognitive, perceptual and emotional assessments, selected for general cognitive screening purposes but not necessarily to detect the largest or most consistent cognitive deficits in early stages of psychosis, suggesting generalisability among these clusters.

In addition to the differences across many cognitive domains between the patients of the clusters, we also found differences with regard to the amount of medication using Chlorpromazin equivalent doses and grey matter volume in frontal, parietal and subcortical brain areas. This emphasizes the complexity of the inter-relationships of cognitive deficits, brain alteration, medication usage and symptom expression, especially when considering that the clustering is based on task and questionnaire data only, and still, differences across all domains - cognition, brain scores, medication and symptoms - have been identified. Several studies indicate an association between higher doses of medication and stronger cognitive deficits86–88. In a birth cohort study, for example, Husa et al.86 showed that a higher lifetime dose of anti-psychotics was associated with lower cognitive performance in schizophrenia patients at the age of 43. Interestingly, a longitudinal study87 investigating the effect of anti-psychotic treatment discontinuation showed that those individuals who did not remain on their medication after a 3.5 year follow up had improved significantly more than those who stayed on their medication even when controlling for symptom severity and cognitive scores at baseline. General non-adherence of medication use, however, does not have the same positive effect on cognition89. Especially, anticholinergic medication has been associated with a high cognitive burden88, which is supported by our results.

Changes in grey matter volume have been associated with an increased risk for psychosis and disease development90–92, and provided the basis for good classification in a recent multicohort-study70, as well as in earlier studies93,94, although classification results are inconsistent95. Our results show that the cluster with the strongest cognitive deficits has increased grey matter volume in three brain networks spanning fronto-parietal and subcortical areas. Across all participants and when correcting for medication we also found a negative correlation between grey matter volume and cognitive performance in several cognitive tests, including general cognition, verbal cognition and reasoning. Interestingly, grey matter volume alterations, especially reductions have been reported in association with schizophrenia41,96–98. Results however depend on the specific region99, illness stage and medication100,101. Interactions between grey matter alterations and various cognitive scores have not been studied extensively102–105. Most studies investigated cognitive alterations in specific domains (e.g., working memory) and often reported positive correlations106–108. Very few studies report negative correlations - increased grey matter volume being linked to reduced cognitive scores. Zhang et al.109 for example showed, comparable with our results, that the performance in the Stroop Color-Word Test’s Card C was negatively correlated with grey matter volumes of frontal and middle frontal brain areas. In a cohort of at-risk mental state for psychosis individuals, Koutsouleris et al.104 found positive and negative correlations between grey matter volume and performance in the trail-making test, with negative correlation reported for cerebellar regions, which is comparable to what we report in the current study. We suspect that the structural covariance network analysis, which specifically aims at finding similarity networks between participants, and then analyses grey matter volume differences within these similar networks might contribute to the difference in directionality of the correlations. Our results however clearly demonstrate differences in the cluster containing the most strongly affected patients - clinically and cognitively. A study by Wenzel et al.103 took a different approach. They attempted to classify individuals of different cognitive clusters using grey matter volume data and a support vector machine approach. They achieved a 60.1% classification accuracy, similar to an early study105, indicating some morphological alterations associated with the cognitive subtypes. Taken together, these differences reported here and in the literature may suggest that grey matter changes are not generally linked to cognitive changes, but rather play a mediating role. This argument would be in the same line of thought as put forward by Palaniyappan110, stating that grey matter changes in multimodal brain regions which have a supervisory function on sensory, emotional and language processing, may link to symptom expression when occurring with functional impairments. Future studies should therefore aim at the combination of additional structural imaging data, such as structural or white matter connectivity, to complement their analysis and potentially identify underlying neuropathological mechanisms.

Our data furthermore reveals a strong link between negative symptoms and cognitive impairments. Investigating PANSS total, we found a step-wise increase in symptom severity from cluster 0 to cluster 2, with the cognitive deficit cluster (cluster 2) showing highest symptom scores. We found, also, that cluster 0, the cognitively spared cluster, showed significantly lower positive symptoms compared to cluster 1 and 2. Furthermore, the globally impaired cluster (cluster 2) revealed increased negative symptoms compared to both other clusters, and increased global psychopathology compared to the cognitively spared cluster (cluster 0), indicating that the cognitive deficits occur in those subjects with strong negative symptoms and a higher severity of general psychopathology111. This is in congruence with Oomen et al.112 who reported three clusters based on only cognitive data with one severely cognitively impaired cluster, which showed general functioning being significantly lower compared to the patients in the other clusters. Interestingly, patients of the severely impaired cluster also showed lower general functioning scores at a trend at 6- and 12-month follow-up. Similar results were reported by Haining et al.84. Tan et al.85 on the other hand did not find associations between the three cognitive clusters and symptom expression, but found that the cognitively impaired subgroup already showed worse academic performance during childhood, early and late adolescence. These findings confirm the critical relevance of cognitive deficits for early detection and functional prediction26–28,84. This often replicated distribution of a severely impaired cluster, indicating that early interventions based on such cluster analysis would be suitable too.

Finally, as our results confirm that patients with non-affective psychosis show stronger cognitive deficits compared to patients with affective psychosis, it is not surprising that non-affective patients are more likely to be in the intermediate and impaired subgroups. Still both patient groups are present in all clusters, with the cognitively intact subgroup consisting of 19/52 and 20/118 patients with affective and non-affective psychosis, respectively, the intermediate group with 28/52 affective and 42/118 non-affective psychosis patients, and the cognitively impaired group with 5/52 affective and 56/118 non-affective psychosis patients. Our results indicate that clustering extends classical patient classification and diagnosis solely based on International Statistical Classification of Diseases (ICD)/Diagnostic and Statistical Manual of Mental Disorders (DSM)113,114, and may provide an additional characterization of patients which may emphasize additional targets of interventions and treatment, such as cognitive remediation, especially for those individuals in the intermediate and in the deficit cluster. This notion is supported by an increased sensitivity in revealing cluster-specific differences across symptom scores, cognitive scores, grey matter volume and medication, when comparisons between diagnosis groups did not show significant effects (Suppl. Table S2).

This study has several limitations: Generally, K-Means115 is a commonly used clustering algorithm that performed well on our data. Nevertheless, there are some drawbacks of this method: First, the algorithm requires a predefined number of clusters. We did not use a purely data-driven number of clusters. Instead, we predefined three clusters based on previous literature, where a spared, an impaired and an intermediate cluster are regularly detected54, and the number of three pre-existing diagnosis groups in the data. As a data-driven control analysis for cluster number specification provided non-conclusive evidence for either two or three clusters, we suggest that future research should aim at replicating the current results in a larger cohort and across a more heterogeneous sample of patients, also including chronic schizophrenia patients. Second, K-Means clustering does not work well with non-spherical cluster or clusters with different sizes116. We, therefore, also performed fuzzy K-means clustering approach which accounts for fuzzy boundaries between subgroups, and is suited for potentially overlapping subgroups73. The age difference between the groups might constitute a third limitation of the study. However, since age was added as a covariate to all analyses, we believe that this aspect did not affect the results to a significant degree. Third, the basis of our clustering approach provided cognitive, perceptual and emotional test scores, which were taken from the standardised NIH toolbox (63,64). Generally, improvement of clustering and identification of cognitive subgroups may be achieved through the selection of specific behavioral tasks and cognitive domains. Moreover, advanced analysis strategies, e.g., computational modelling may improve clustering16,17,117, as it provides the opportunity to identify and mathematically differentiate behavioral parameters, which were found to be reliable and unique across individuals118.

In conclusion, our results provide evidence for the presence of three cognitive subgroups - one cognitively intact, one intermediate and one deficit group - confirming previous findings. This study however extends those results, showing that patients within those three clusters also differ with respect to current medication dosage and grey matter volume in fronto-parietal and subcortical regions. Our results therefore emphasize the complex inter-relations between cognition, symptoms, brain structure and medication, drawing attention to the pivotal role of alterations in cognition as a factor for the selection of treatments and interventions.

Supplementary Information

Supplementary Information.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-71316-3.

Acknowledgements

Research using Human Connectome Project for Early Psychosis (HCP-EP) data reported in this publication was supported by the National Institute of Mental Health of the National Institutes of Health under Award Number U01MH109977. The HCP-EP 1.1 Release data used in this report came from DOI: 10.15154/1522899.

Author contributions

F.K., K.B., A.W. conceptualisation; KK preprocessing of structural brain data; F.K. and K.B. formal analysis of cognitive data and clustering analysis; F.K. and K.B. writing of first draft; F.K., K.B., A.W. and K.K. editing and revising of manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Data availability

All processed data and code may be accessed via: https://github.com/KatharinaBracher/earlypsychosis_clustering.

Competing interest

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Fusar-Poli P Deste G Smieskova R Barlati S Yung AR Howes O Stieglitz R-D Vita A McGuire P Borgwardt S Cognitive functioning in prodromal psychosis: A meta-analysis Arch. Gen. Psychiatry 2012 69 6 562 571 10.1001/archgenpsychiatry.2011.1592 22664547
Fusar-Poli, P. et al. Cognitive functioning in prodromal psychosis: A meta-analysis. Arch. Gen. Psychiatry 69(6), 562–571. 10.1001/archgenpsychiatry.2011.1592 (2012).22664547 10.1001/archgenpsychiatry.2011.1592
2. Barch DM Ceaser A Cognition in schizophrenia: Core psychological and neural mechanisms Trends Cogn. Sci. 2012 16 1 27 34 10.1016/j.tics.2011.11.015 22169777
Barch, D. M. & Ceaser, A. Cognition in schizophrenia: Core psychological and neural mechanisms. Trends Cogn. Sci. 16(1), 27–34 (2012).22169777 10.1016/j.tics.2011.11.015
3. Dienel SJ Lewis DA Alterations in cortical interneurons and cognitive function in schizophrenia Neurobiol. Dis. 2019 131 104208 10.1016/j.nbd.2018.06.020 29936230
Dienel, S. J. & Lewis, D. A. Alterations in cortical interneurons and cognitive function in schizophrenia. Neurobiol. Dis. 131, 104208. 10.1016/j.nbd.2018.06.020 (2019).29936230 10.1016/j.nbd.2018.06.020
4. Green MF Harvey PD Cognition in schizophrenia: Past, present, and future Schizophr. Res. Cogn. 2014 1 1 e1 e9 10.1016/j.scog.2014.02.001 25254156
Green, M. F. & Harvey, P. D. Cognition in schizophrenia: Past, present, and future. Schizophr. Res. Cogn. 1(1), e1–e9 (2014).25254156 10.1016/j.scog.2014.02.001
5. Zanello A Curtis L Bâ MB Merlo MC Working memory impairments in first-episode psychosis and chronic schizophrenia Psychiatry Res. 2009 165 1-2 10 18 10.1016/j.psychres.2007.10.006 19046607
Zanello, A., Curtis, L., Bâ, M. B. & Merlo, M. C. Working memory impairments in first-episode psychosis and chronic schizophrenia. Psychiatry Res. 165(1–2), 10–18 (2009).19046607 10.1016/j.psychres.2007.10.006
6. Wood SJ Pantelis C Proffitt T Phillips L Stuart G Buchanan J-A Mahony K Brewer W Smith D McGorry P Spatial working memory ability is a marker of risk-for-psychosis Psychol. Med. 2003 33 7 1239 1247 10.1017/S0033291703008067 14580078
Wood, S. J. et al. Spatial working memory ability is a marker of risk-for-psychosis. Psychol. Med. 33(7), 1239–1247 (2003).14580078 10.1017/S0033291703008067
7. Cornblatt BA Malhotra AK Impaired attention as an endophenotype for molecular genetic studies of schizophrenia Am. J. Med. Genet. 2001 105 1 11 15 10.1002/1096-8628(20010108)105:1<11::AID-AJMG1045>3.0.CO;2-G 11424979
Cornblatt, B. A. & Malhotra, A. K. Impaired attention as an endophenotype for molecular genetic studies of schizophrenia. Am. J. Med. Genet. 105(1), 11–15 (2001).11424979 10.1002/1096-8628(20010108)105:1<11::AID-AJMG1045>3.0.CO;2-G
8. Aase I Kompus K Gisselgård J Joa I Johannessen JO Brønnick K Language lateralization and auditory attention impairment in young adults at ultra-high risk for psychosis: A dichotic listening study Front. Psychol. 2018 9 608 10.3389/fpsyg.2018.00608 29755393
Aase, I. et al. Language lateralization and auditory attention impairment in young adults at ultra-high risk for psychosis: A dichotic listening study. Front. Psychol. 9, 608 (2018).29755393 10.3389/fpsyg.2018.00608
9. Garety P Joyce E Jolley S Emsley R Waller H Kuipers E Bebbington P Fowler D Dunn G Freeman D Neuropsychological functioning and jumping to conclusions in delusions Schizophr. Res. 2013 150 2–3 570 574 10.1016/j.schres.2013.08.035 24075604
Garety, P. et al. Neuropsychological functioning and jumping to conclusions in delusions. Schizophr. Res. 150(2–3), 570–574. 10.1016/j.schres.2013.08.035 (2013).24075604 10.1016/j.schres.2013.08.035
10. Ermakova AO Gileadi N Knolle F Justicia A Anderson R Fletcher PC Moutoussis M Murray GK Cost evaluation during decision-making in patients at early stages of psychosis Comput. Psychiatry 2019 3 18 39 10.1162/CPSY_a_00020
Ermakova, A. O. et al. Cost evaluation during decision-making in patients at early stages of psychosis. Comput. Psychiatry 3, 18–39 (2019).10.1162/CPSY_a_00020
11. Sterzer P Voss M Schlagenhauf F Heinz A Decision-making in schizophrenia: A predictive-coding perspective Neuroimage 2019 190 133 143 10.1016/j.neuroimage.2018.05.074 29860087
Sterzer, P., Voss, M., Schlagenhauf, F. & Heinz, A. Decision-making in schizophrenia: A predictive-coding perspective. Neuroimage 190, 133–143 (2019).29860087 10.1016/j.neuroimage.2018.05.074
12. Ermakova AO Knolle F Justicia A Bullmore ET Jones PB Robbins TW Fletcher PC Murray GK Abnormal reward prediction-error signalling in antipsychotic naive individuals with first-episode psychosis or clinical risk for psychosis Neuropsychopharmacology 2018 43 8 1691 1699 10.1038/s41386-018-0056-2 29748629
Ermakova, A. O. et al. Abnormal reward prediction-error signalling in antipsychotic naive individuals with first-episode psychosis or clinical risk for psychosis. Neuropsychopharmacology 43(8), 1691–1699 (2018).29748629 10.1038/s41386-018-0056-2
13. Brandl F Knolle F Avram M Leucht C Yakushev I Priller J Leucht S Ziegler S Wunderlich K Sorg C Negative symptoms, striatal dopamine and model-free reward decision-making in schizophrenia Brain 2023 146 2 767 777 10.1093/brain/awac268 35875972
Brandl, F. et al. Negative symptoms, striatal dopamine and model-free reward decision-making in schizophrenia. Brain 146(2), 767–777 (2023).35875972 10.1093/brain/awac268
14. Knolle F Ermakova AO Justicia A Fletcher PC Bunzeck N Düzel E Murray GK Brain responses to different types of salience in antipsychotic naïve first episode psychosis: An fMRI study Transl. Psychiatry 2018 8 1 1 13 10.1038/s41398-018-0250-3 29317594
Knolle, F. et al. Brain responses to different types of salience in antipsychotic naïve first episode psychosis: An fMRI study. Transl. Psychiatry 8(1), 1–13 (2018).29317594 10.1038/s41398-018-0250-3
15. Kesby JP Murray GK Knolle F Neural circuitry of salience and reward processing in psychosis Biol. Psychiatry Glob. Open Sci. 2021 10.1016/j.bpsgos.2021.12.003 36712572
Kesby, J. P., Murray, G. K. & Knolle, F. Neural circuitry of salience and reward processing in psychosis. Biol. Psychiatry Glob. Open Sci.[SPACE]10.1016/j.bpsgos.2021.12.003 (2021).36712572 10.1016/j.bpsgos.2021.12.003
16. Knolle F Sterner E Moutoussis M Adams RA Griffin JD Haarsma J Taverne H Goodyer IM Fletcher PC Murray GK Action selection in early stages of psychosis: An active inference approach J. Psychiatry Neurosci. 2023 48 1 E78 E89 10.1503/jpn.220141 36810306
Knolle, F. et al. Action selection in early stages of psychosis: An active inference approach. J. Psychiatry Neurosci. 48(1), E78–E89 (2023).36810306 10.1503/jpn.220141
17. Montagnese M Knolle F Haarsma J Griffin JD Richards A Vertes PE Kiddle B Fletcher PC Jones PB Owen MJ Reinforcement learning as an intermediate phenotype in psychosis? Deficits sensitive to illness stage but not associated with polygenic risk of schizophrenia in the general population Schizophr. Res. 2020 222 389 396 10.1016/j.schres.2020.04.022 32389614
Montagnese, M. et al. Reinforcement learning as an intermediate phenotype in psychosis? Deficits sensitive to illness stage but not associated with polygenic risk of schizophrenia in the general population. Schizophr. Res. 222, 389–396 (2020).32389614 10.1016/j.schres.2020.04.022
18. Knolle F Sen P Culbreth AJ Koch K Schmitz-Koep B Guersel DA Wunderlich K Avram M Sorg C Brandl F Modelling model-based and model-free decision-making in a transdiagnostic sample to investigate disorder-specific and transdiagnostic alterations medRxiv 2023 10.1101/2023.12.11.23299814
Knolle, F. et al. Modelling model-based and model-free decision-making in a transdiagnostic sample to investigate disorder-specific and transdiagnostic alterations. medRxiv[SPACE]10.1101/2023.12.11.23299814 (2023).10.1101/2023.12.11.23299814
19. Morris R Rushe T Woodruffe P Murray R Problem solving in schizophrenia: A specific deficit in planning ability Schizophr. Res. 1995 14 3 235 246 10.1016/0920-9964(94)00044-9 7766535
Morris, R., Rushe, T., Woodruffe, P. & Murray, R. Problem solving in schizophrenia: A specific deficit in planning ability. Schizophr. Res. 14(3), 235–246. 10.1016/0920-9964(94)00044-9 (1995).7766535 10.1016/0920-9964(94)00044-9
20. Revheim N Schechter I Kim D Silipo G Allingham B Butler P Javitt DC Neurocognitive and symptom correlates of daily problem-solving skills in schizophrenia Schizophr. Res. 2006 83 2-3 237 245 10.1016/j.schres.2005.12.849 16443347
Revheim, N. et al. Neurocognitive and symptom correlates of daily problem-solving skills in schizophrenia. Schizophr. Res. 83(2–3), 237–245 (2006).16443347 10.1016/j.schres.2005.12.849
21. Liu Y Wang G Jin H Lyu H Liu Y Guo W Shi C Meyers J Wang J Zhao J Cognitive deficits in subjects at risk for psychosis, first-episode and chronic schizophrenia patients Psychiatry Res. 2019 274 235 242 10.1016/j.psychres.2019.01.089 30818145
Liu, Y. et al. Cognitive deficits in subjects at risk for psychosis, first-episode and chronic schizophrenia patients. Psychiatry Res. 274, 235–242 (2019).30818145 10.1016/j.psychres.2019.01.089
22. Sheffield JM Karcher NR Barch DM Cognitive deficits in psychotic disorders: A lifespan perspective Neuropsychol. Rev. 2018 28 4 509 533 10.1007/s11065-018-9388-2 30343458
Sheffield, J. M., Karcher, N. R. & Barch, D. M. Cognitive deficits in psychotic disorders: A lifespan perspective. Neuropsychol. Rev. 28(4), 509–533 (2018).30343458 10.1007/s11065-018-9388-2
23. Gold JM Harvey PD Cognitive deficits in schizophrenia Psychiatr. Clin. N. Am. 1993 16 2 295 312 10.1016/S0193-953X(18)30175-8
Gold, J. M. & Harvey, P. D. Cognitive deficits in schizophrenia. Psychiatr. Clin. N. Am. 16(2), 295–312 (1993).10.1016/S0193-953X(18)30175-8
24. Fioravanti M Carlone O Vitale B Cinti ME Clare L A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia Neuropsychol. Rev. 2005 15 2 73 95 10.1007/s11065-005-6254-9 16211467
Fioravanti, M., Carlone, O., Vitale, B., Cinti, M. E. & Clare, L. A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychol. Rev. 15(2), 73–95 (2005).16211467 10.1007/s11065-005-6254-9
25. Kelly S Guimond S Lyall A Stone WS Shenton ME Keshavan M Seidman LJ Neural correlates of cognitive deficits across developmental phases of schizophrenia Neurobiol. Dis. 2019 131 104353 10.1016/j.nbd.2018.12.013 30582983
Kelly, S. et al. Neural correlates of cognitive deficits across developmental phases of schizophrenia. Neurobiol. Dis. 131, 104353 (2019).30582983 10.1016/j.nbd.2018.12.013
26. Green MF Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia J. Clin. Psychiatry 2016 77 suppl 2 8569 10.4088/JCP.14074su1c.02
Green, M. F. Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia. J. Clin. Psychiatry 77(suppl 2), 8569 (2016).10.4088/JCP.14074su1c.02
27. Fervaha G Takeuchi H Foussias G Hahn MK Agid O Remington G Achievement motivation in early schizophrenia: Relationship with symptoms, cognition and functional outcome Early Interv. Psychiatry 2018 12 6 1038 1044 10.1111/eip.12405 28230315
Fervaha, G. et al. Achievement motivation in early schizophrenia: Relationship with symptoms, cognition and functional outcome. Early Interv. Psychiatry 12(6), 1038–1044. 10.1111/eip.12405 (2018).28230315 10.1111/eip.12405
28. Allott K Liu P Proffitt T-M Killackey E Cognition at illness onset as a predictor of later functional outcome in early psychosis: Systematic review and methodological critique Schizophr. Res. 2011 125 2–3 221 235 10.1016/j.schres.2010.11.001 21111577
Allott, K., Liu, P., Proffitt, T.-M. & Killackey, E. Cognition at illness onset as a predictor of later functional outcome in early psychosis: Systematic review and methodological critique. Schizophr. Res. 125(2–3), 221–235 (2011).21111577 10.1016/j.schres.2010.11.001
29. Van Winkel R Myin-Germeys I De Hert M Delespaul P Peuskens J Van Os J The association between cognition and functional outcome in first-episode patients with schizophrenia: Mystery resolved? Acta Psychiatr. Scand. 2007 116 2 119 124 10.1111/j.1600-0447.2007.01014.x 17650273
Van Winkel, R. et al. The association between cognition and functional outcome in first-episode patients with schizophrenia: Mystery resolved?. Acta Psychiatr. Scand. 116(2), 119–124 (2007).17650273 10.1111/j.1600-0447.2007.01014.x
30. Reichenberg A Harvey PD Bowie CR Mojtabai R Rabinowitz J Heaton RK Bromet E Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders Schizophr. Bull. 2009 35 5 1022 1029 10.1093/schbul/sbn044 18495643
Reichenberg, A. et al. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr. Bull. 35(5), 1022–1029 (2009).18495643 10.1093/schbul/sbn044
31. McCleery A Nuechterlein KH Cognitive impairment in psychotic illness: Prevalence, profile of impairment, developmental course, and treatment considerations Dialogues Clin. Neurosci. 2022 10.31887/DCNS.2019.21.3/amccleery
McCleery, A. & Nuechterlein, K. H. Cognitive impairment in psychotic illness: Prevalence, profile of impairment, developmental course, and treatment considerations. Dialogues Clin. Neurosci.[SPACE]10.31887/DCNS.2019.21.3/amccleery (2022).10.31887/DCNS.2019.21.3/amccleery
32. Keefe RS Fenton WS How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr. Bull. 2007 33 4 912 920 10.1093/schbul/sbm046 17567627
Keefe, R. S. & Fenton, W. S. How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophr. Bull. 33(4), 912–920 (2007).17567627 10.1093/schbul/sbm046
33. Sinkeviciute I Begemann M Prikken M Oranje B Johnsen E Lei WU Hugdahl K Kroken RA Rau C Jacobs JD Efficacy of different types of cognitive enhancers for patients with schizophrenia: A meta-analysis NPJ Schizophr. 2018 4 1 1 14 10.1038/s41537-018-0064-6 29321530
Sinkeviciute, I. et al. Efficacy of different types of cognitive enhancers for patients with schizophrenia: A meta-analysis. NPJ Schizophr. 4(1), 1–14 (2018).29321530 10.1038/s41537-018-0064-6
34. Tripathi A Kar SK Shukla R Cognitive deficits in schizophrenia: Understanding the biological correlates and remediation strategies Clin. Psychopharmacol. Neurosci. 2018 16 1 7 10.9758/cpn.2018.16.1.7 29397662
Tripathi, A., Kar, S. K. & Shukla, R. Cognitive deficits in schizophrenia: Understanding the biological correlates and remediation strategies. Clin. Psychopharmacol. Neurosci. 16(1), 7 (2018).29397662 10.9758/cpn.2018.16.1.7
35. Vita A Barlati S Ceraso A Nibbio G Ariu C Deste G Wykes T Effectiveness, core elements, and moderators of response of cognitive remediation for schizophrenia: A systematic review and meta-analysis of randomized clinical trials JAMA Psychiat. 2021 78 8 848 858 10.1001/jamapsychiatry.2021.0620
Vita, A. et al. Effectiveness, core elements, and moderators of response of cognitive remediation for schizophrenia: A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiat. 78(8), 848–858 (2021).10.1001/jamapsychiatry.2021.0620
36. Amoretti S Rosa AR Mezquida G Cabrera B Ribeiro M Molina M Bioque M Lobo A González-Pinto A Fraguas D The impact of cognitive reserve, cognition and clinical symptoms on psychosocial functioning in first-episode psychoses Psychol. Med. 2022 52 3 526 537 10.1017/S0033291720002226 32900395
Amoretti, S. et al. The impact of cognitive reserve, cognition and clinical symptoms on psychosocial functioning in first-episode psychoses. Psychol. Med. 52(3), 526–537. 10.1017/S0033291720002226 (2022).32900395 10.1017/S0033291720002226
37. Santesteban-Echarri O Paino M Rice S González-Blanch C McGorry P Gleeson J Alvarez-Jimenez M Predictors of functional recovery in first-episode psychosis: A systematic review and meta-analysis of longitudinal studies Clin. Psychol. Rev. 2017 58 59 75 10.1016/j.cpr.2017.09.007 29042139
Santesteban-Echarri, O. et al. Predictors of functional recovery in first-episode psychosis: A systematic review and meta-analysis of longitudinal studies. Clin. Psychol. Rev. 58, 59–75 (2017).29042139 10.1016/j.cpr.2017.09.007
38. Lewis DA Cortical circuit dysfunction and cognitive deficits in schizophrenia-implications for preemptive interventions Eur. J. Neurosci. 2012 35 12 1871 1878 10.1111/j.1460-9568.2012.08156.x 22708598
Lewis, D. A. Cortical circuit dysfunction and cognitive deficits in schizophrenia-implications for preemptive interventions. Eur. J. Neurosci. 35(12), 1871–1878 (2012).22708598 10.1111/j.1460-9568.2012.08156.x
39. Xu M-Y Wong AH GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia Acta Pharmacol. Sin. 2018 39 5 733 753 10.1038/aps.2017.172 29565038
Xu, M.-Y. & Wong, A. H. GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia. Acta Pharmacol. Sin. 39(5), 733–753 (2018).29565038 10.1038/aps.2017.172
40. Kambeitz J Kambeitz-Ilankovic L Cabral C Dwyer DB Calhoun VD Van Den Heuvel MP Falkai P Koutsouleris N Malchow B Aberrant functional whole-brain network architecture in patients with schizophrenia: A meta-analysis Schizophr. Bull. 2016 42 S13 S21 10.1093/schbul/sbv174 27460615
Kambeitz, J. et al. Aberrant functional whole-brain network architecture in patients with schizophrenia: A meta-analysis. Schizophr. Bull. 42, S13–S21 (2016).27460615 10.1093/schbul/sbv174
41. Fusar-Poli P Radua J McGuire P Borgwardt S Neuroanatomical maps of psychosis onset: Voxel-wise meta-analysis of antipsychotic-naive VBM studies Schizophr. Bull. 2012 38 6 1297 1307 10.1093/schbul/sbr134 22080494
Fusar-Poli, P., Radua, J., McGuire, P. & Borgwardt, S. Neuroanatomical maps of psychosis onset: Voxel-wise meta-analysis of antipsychotic-naive VBM studies. Schizophr. Bull. 38(6), 1297–1307 (2012).22080494 10.1093/schbul/sbr134
42. Minatogawa-Chang TM Schaufelberger MS Ayres AM Duran FL Gutt EK Murray RM Rushe TM McGuire PK Menezes PR Scazufca M Cognitive performance is related to cortical grey matter volumes in early stages of schizophrenia: A population-based study of first-episode psychosis Schizophr. Res. 2009 113 2–3 200 209 10.1016/j.schres.2009.06.020 19616413
Minatogawa-Chang, T. M. et al. Cognitive performance is related to cortical grey matter volumes in early stages of schizophrenia: A population-based study of first-episode psychosis. Schizophr. Res. 113(2–3), 200–209 (2009).19616413 10.1016/j.schres.2009.06.020
43. Banaj N Piras F Piras F Ciullo V Iorio M Battaglia C Pantoli D Ducci G Spalletta G Cognitive and psychopathology correlates of brain white/grey matter structure in severely psychotic schizophrenic inpatients Schizophr. Res. Cogn. 2018 12 29 36 10.1016/j.scog.2018.02.001 29527507
Banaj, N. et al. Cognitive and psychopathology correlates of brain white/grey matter structure in severely psychotic schizophrenic inpatients. Schizophr. Res. Cogn. 12, 29–36 (2018).29527507 10.1016/j.scog.2018.02.001
44. Van Rheenen TE Cropley V Zalesky A Bousman C Wells R Bruggemann J Sundram S Weinberg D Lenroot RK Pereira A Widespread volumetric reductions in schizophrenia and schizoaffective patients displaying compromised cognitive abilities Schizophr. Bull. 2018 44 3 560 574 10.1093/schbul/sbx109 28981831
Van Rheenen, T. E. et al. Widespread volumetric reductions in schizophrenia and schizoaffective patients displaying compromised cognitive abilities. Schizophr. Bull. 44(3), 560–574 (2018).28981831 10.1093/schbul/sbx109
45. Fagerlund B Pagsberg AK Hemmingsen RP Cognitive deficits and levels of IQ in adolescent onset schizophrenia and other psychotic disorders Schizophr. Res. 2006 85 1-3 30 39 10.1016/j.schres.2006.03.004 16626945
Fagerlund, B., Pagsberg, A. K. & Hemmingsen, R. P. Cognitive deficits and levels of IQ in adolescent onset schizophrenia and other psychotic disorders. Schizophr. Res. 85(1–3), 30–39 (2006).16626945 10.1016/j.schres.2006.03.004
46. Aas M Dazzan P Fisher HL Morgan C Morgan K Reichenberg A Zanelli J Fearon P Jones PB Murray RM Childhood trauma and cognitive function in first-episode affective and non-affective psychosis Schizophr. Res. 2011 129 1 12 19 10.1016/j.schres.2011.03.017 21601792
Aas, M. et al. Childhood trauma and cognitive function in first-episode affective and non-affective psychosis. Schizophr. Res. 129(1), 12–19 (2011).21601792 10.1016/j.schres.2011.03.017
47. Barch DM Sheffield JM Cognitive impairments in psychotic disorders: Common mechanisms and measurement World Psychiatry 2014 13 3 224 232 10.1002/wps.20145 25273286
Barch, D. M. & Sheffield, J. M. Cognitive impairments in psychotic disorders: Common mechanisms and measurement. World Psychiatry 13(3), 224–232 (2014).25273286 10.1002/wps.20145
48. Craddock N O’Donovan MC Owen MJ Psychosis genetics: Modeling the relationship between schizophrenia, bipolar disorder, and mixed (or “schizoaffective” psychoses Schizophr. Bull. 2009 35 3 482 490 10.1093/schbul/sbp020 19329560
Craddock, N., O’Donovan, M. C. & Owen, M. J. Psychosis genetics: Modeling the relationship between schizophrenia, bipolar disorder, and mixed (or “schizoaffective” psychoses. Schizophr. Bull. 35(3), 482–490 (2009).19329560 10.1093/schbul/sbp020
49. Lewandowski KE Bouix S Ongur D Neuroprogression across the early course of psychosis J. Psychiatry Brain Sci. 2020 10.20900/jpbs.20200002
Lewandowski, K. E., Bouix, S. & Ongur, D. Neuroprogression across the early course of psychosis. J. Psychiatry Brain Sci.[SPACE]10.20900/jpbs.20200002 (2020).10.20900/jpbs.20200002
50. Mark W Toulopoulou T Cognitive intermediate phenotype and genetic risk for psychosis Curr. Opin. Neurobiol. 2016 36 23 30 10.1016/j.conb.2015.08.008 26363129
Mark, W. & Toulopoulou, T. Cognitive intermediate phenotype and genetic risk for psychosis. Curr. Opin. Neurobiol. 36, 23–30. 10.1016/j.conb.2015.08.008 (2016).26363129 10.1016/j.conb.2015.08.008
51. Shafee R Nanda P Padmanabhan JL Tandon N Alliey-Rodriguez N Kalapurakkel S Weiner DJ Gur RE Keefe RS Hill SK Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls Transl. Psychiatry 2018 8 1 1 9 10.1038/s41398-018-0124-8 29317594
Shafee, R. et al. Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls. Transl. Psychiatry 8(1), 1–9 (2018).29317594 10.1038/s41398-018-0124-8
52. Lewandowski KE Baker JT McCarthy JM Norris LA Öngür D Reproducibility of cognitive profiles in psychosis using cluster analysis J. Int. Neuropsychol. Soc. 2018 24 4 382 390 10.1017/S1355617717001047 29041995
Lewandowski, K. E., Baker, J. T., McCarthy, J. M., Norris, L. A. & Öngür, D. Reproducibility of cognitive profiles in psychosis using cluster analysis. J. Int. Neuropsychol. Soc. 24(4), 382–390. 10.1017/S1355617717001047 (2018).29041995 10.1017/S1355617717001047
53. Carruthers SP Van Rheenen TE Karantonis JA Rossell SL Characterising demographic, clinical and functional features of cognitive subgroups in schizophrenia spectrum disorders: A systematic review Neuropsychol. Rev. 2022 10.1007/s11065-021-09525-0 35194692
Carruthers, S. P., Van Rheenen, T. E., Karantonis, J. A. & Rossell, S. L. Characterising demographic, clinical and functional features of cognitive subgroups in schizophrenia spectrum disorders: A systematic review. Neuropsychol. Rev.[SPACE]10.1007/s11065-021-09525-0 (2022).35194692 10.1007/s11065-021-09525-0
54. Green MJ Girshkin L Kremerskothen K Watkeys O Quidé Y A systematic review of studies reporting data-driven cognitive subtypes across the psychosis spectrum Neuropsychol. Rev. 2020 30 4 446 460 10.1007/s11065-019-09422-7 31853717
Green, M. J., Girshkin, L., Kremerskothen, K., Watkeys, O. & Quidé, Y. A systematic review of studies reporting data-driven cognitive subtypes across the psychosis spectrum. Neuropsychol. Rev. 30(4), 446–460 (2020).31853717 10.1007/s11065-019-09422-7
55. Bowie CR Grossman M Gupta M Oyewumi LK Harvey PD Cognitive remediation in schizophrenia: Efficacy and effectiveness in patients with early versus long-term course of illness Early Interv. Psychiatry 2014 8 1 32 38 10.1111/eip.12029 23343011
Bowie, C. R., Grossman, M., Gupta, M., Oyewumi, L. K. & Harvey, P. D. Cognitive remediation in schizophrenia: Efficacy and effectiveness in patients with early versus long-term course of illness. Early Interv. Psychiatry 8(1), 32–38 (2014).23343011 10.1111/eip.12029
56. Reeder C Smedley N Butt K Bogner D Wykes T Cognitive predictors of social functioning improvements following cognitive remediation for schizophrenia Schizophr. Bull. 2006 32 S123 S131 10.1093/schbul/sbl019 16901950
Reeder, C., Smedley, N., Butt, K., Bogner, D. & Wykes, T. Cognitive predictors of social functioning improvements following cognitive remediation for schizophrenia. Schizophr. Bull. 32, S123–S131 (2006).16901950 10.1093/schbul/sbl019
57. Kurtz MM Seltzer JC Fujimoto M Shagan DS Wexler BE Predictors of change in life skills in schizophrenia after cognitive remediation Schizophr. Res. 2009 107 2–3 267 274 10.1016/j.schres.2008.10.014 19006657
Kurtz, M. M., Seltzer, J. C., Fujimoto, M., Shagan, D. S. & Wexler, B. E. Predictors of change in life skills in schizophrenia after cognitive remediation. Schizophr. Res. 107(2–3), 267–274 (2009).19006657 10.1016/j.schres.2008.10.014
58. Kambeitz-Ilankovic L Betz LT Dominke C Haas SS Subramaniam K Fisher M Vinogradov S Koutsouleris N Kambeitz J Multi-outcome meta-analysis (MOMA) of cognitive remediation in schizophrenia: Revisiting the relevance of human coaching and elucidating interplay between multiple outcomes Neurosci. Biobehav. Rev. 2019 107 828 845 10.1016/j.neubiorev.2019.09.031 31557548
Kambeitz-Ilankovic, L. et al. Multi-outcome meta-analysis (MOMA) of cognitive remediation in schizophrenia: Revisiting the relevance of human coaching and elucidating interplay between multiple outcomes. Neurosci. Biobehav. Rev. 107, 828–845 (2019).31557548 10.1016/j.neubiorev.2019.09.031
59. Lewandowski KE Bouix S Ongur D Shenton ME Neuroprogression across the early course of psychosis J. Psychiatry Brain Sci. 2020 10.20900/jpbs.20200002
Lewandowski, K. E., Bouix, S., Ongur, D. & Shenton, M. E. Neuroprogression across the early course of psychosis. J. Psychiatry Brain Sci.[SPACE]10.20900/jpbs.20200002 (2020).10.20900/jpbs.20200002
60. Breier, A., Shenton, M., Holt, D., Keshavan, M., Öngür, D., Seidman, L. HCP Early Psychosis 1.0 Data Release: Reference Manual 9. Tech. rep. August. Indianapolis: Boston, MA: Brigham and Womenś Hospital, Beth Israel Deaconess-Massachusetts Mental Health Center, McLean Hospital, Massachusetts General Hospital (2021)
61. First, M., Williams, J., Karg, R., Spitzer, R. Structured Clinical Interview for DSM-5-Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV) (2015) Arlington. VA: American Psychiatric Association ().
62. Kay SR Fiszbein A Opler LA The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr. Bull. 1987 13 2 261 276 10.1093/schbul/13.2.261 3616518
Kay, S. R., Fiszbein, A. & Opler, L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13(2), 261–276 (1987).3616518 10.1093/schbul/13.2.261
63. Gershon RC Wagster MV Hendrie HC Fox NA Cook KF Nowinski CJ NIH toolbox for assessment of neurological and behavioral function Neurology 2013 80 S2 S6 10.1212/WNL.0b013e3182872e5f 23479538
Gershon, R. C. et al. NIH toolbox for assessment of neurological and behavioral function. Neurology 80, S2–S6 (2013).23479538 10.1212/WNL.0b013e3182872e5f
64. [Anonymous]. National Institutes of Health Toolbox Cognition Battery (NIH toolbox CB): Validation for Children Between 3 and 15 years. Monographs of the Society for Research in Child Development 78, 147–149. 10.1111/mono.12040.
65. Gur RC Richard J Hughett P Calkins ME Macy L Bilker WB Brensinger C Gur RE A cognitive neuroscience-based computerized battery for efficient measurement of individual differences: standardization and initial construct validation J. Neurosci. Methods 2010 187 2 254 262 10.1016/j.jneumeth.2009.11.017 19945485
Gur, R. C. et al. A cognitive neuroscience-based computerized battery for efficient measurement of individual differences: standardization and initial construct validation. J. Neurosci. Methods 187(2), 254–262 (2010).19945485 10.1016/j.jneumeth.2009.11.017
66. Wechsler, D. Wechsler abbreviated scale of intelligence (1999).
67. Seidman LJ Meyer EC Giuliano AJ Breiter HC Goldstein JM Kremen WS Thermenos HW Toomey R Stone WS Tsuang MT Auditory working memory impairments in individuals at familial high risk for schizophrenia Neuropsychology 2012 26 3 288 10.1037/a0027970 22563872
Seidman, L. J. et al. Auditory working memory impairments in individuals at familial high risk for schizophrenia. Neuropsychology 26(3), 288 (2012).22563872 10.1037/a0027970
68. Kalantan Z Alqahtani N A study of principal components analysis for mixed data Int. J. Adv. Appl. Sci. 2019 6 99 104 10.21833/ijaas.2019.12.012
Kalantan, Z. & Alqahtani, N. A study of principal components analysis for mixed data. Int. J. Adv. Appl. Sci. 6, 99–104. 10.21833/ijaas.2019.12.012 (2019).10.21833/ijaas.2019.12.012
69. Sperber, C. The use of principal component and factor analysis to measure fundamental cognitive processes in neuropsychological data. bioRxiv (2022). 10.1101/2021.11.10.468133. eprint: https://www.biorxiv.org/content/early/2022/03/19/2021.11.10.468133.full.pdf.
70. Knolle F Arumugham SS Barker RA Chee MW Justicia A Kamble N Lee J Liu S Lenka A Lewis SJ A multicentre study on grey matter morphometric biomarkers for classifying early schizophrenia and Parkinson’s disease psychosis npj Parkinson ś Dis. 2023 9 1 87 10.1038/s41531-023-00522-z
Knolle, F. et al. A multicentre study on grey matter morphometric biomarkers for classifying early schizophrenia and Parkinson’s disease psychosis. npj Parkinson ś Dis. 9(1), 87 (2023).10.1038/s41531-023-00522-z
71. Koch K Rodriguez-Manrique D Rus-Oswald OG Gürsel DA Berberich G Kunz M Zimmer C Homogeneous grey matter patterns in patients with obsessive-compulsive disorder NeuroImage Clin. 2021 31 102727 10.1016/j.nicl.2021.102727 34146774
Koch, K. et al. Homogeneous grey matter patterns in patients with obsessive-compulsive disorder. NeuroImage Clin. 31, 102727 (2021).34146774 10.1016/j.nicl.2021.102727
72. Pichet Binette A Gonneaud J Vogel JW La Joie R Rosa-Neto P Collins DL Poirier J Breitner JC Villeneuve S Vachon-Presseau E Morphometric network differences in ageing versus Alzheimer’s disease dementia Brain 2020 143 2 635 649 10.1093/brain/awz414 32040564
Pichet Binette, A. et al. Morphometric network differences in ageing versus Alzheimer’s disease dementia. Brain 143(2), 635–649 (2020).32040564 10.1093/brain/awz414
73. Majumdar K Human scalp EEG processing: Various soft computing approaches Appl. Soft Comput. 2011 11 8 4433 4447 10.1016/j.asoc.2011.07.004
Majumdar, K. Human scalp EEG processing: Various soft computing approaches. Appl. Soft Comput. 11(8), 4433–4447. 10.1016/j.asoc.2011.07.004 (2011).10.1016/j.asoc.2011.07.004
74. Bezdek JC Ehrlich R Full W FCM: The fuzzy c-means clustering algorithm Comput. Geosci. 1984 10 2–3 191 203 10.1016/0098-3004(84)90020-7
Bezdek, J. C., Ehrlich, R. & Full, W. FCM: The fuzzy c-means clustering algorithm. Comput. Geosci. 10(2–3), 191–203. 10.1016/0098-3004(84)90020-7 (1984).10.1016/0098-3004(84)90020-7
75. Verma RK Tiwari R Thakur PS Partition coefficient and partition entropy in fuzzy c means clustering J. Sci. Res. Rep. 2023 29 12 1 6 10.9734/jsrr/2023/v29i121812
Verma, R. K., Tiwari, R. & Thakur, P. S. Partition coefficient and partition entropy in fuzzy c means clustering. J. Sci. Res. Rep. 29(12), 1–6 (2023).10.9734/jsrr/2023/v29i121812
76. Dias, M. L. D. Fuzzy-c-means: An implementation of Fuzzy -means clustering algorithm (2019) 10.5281/zenodo.3066222.
77. Kim S ppcor: An R package for a fast calculation to semi-partial correlation coefficients Commun. Stat. Appl. Methods 2015 22 6 665 26688802
Kim, S. ppcor: An R package for a fast calculation to semi-partial correlation coefficients. Commun. Stat. Appl. Methods 22(6), 665 (2015).26688802
78. R Core Team. R: A Language and Environment for Statistical Computing. ISBN 3-900051-07-0. R Foundation for Statistical Computing. Vienna, Austria (2013)
79. Ji JL Helmer M Fonteneau C Burt JB Tamayo Z Demšar J Adkinson BD Savić A Preller KH Moujaes F Vollenweider FX Martin WJ Repovš G Murray JD Anticevic A Mapping brain-behavior space relationships along the psychosis spectrum eLife 2021 10.7554/eLife.66968 34905486
Ji, J. L. et al. Mapping brain-behavior space relationships along the psychosis spectrum. eLife[SPACE]10.7554/eLife.66968 (2021).34905486 10.7554/eLife.66968
80. Lewandowski K Sperry S Cohen B Öngür D Cognitive variability in psychotic disorders: A cross-diagnostic cluster analysis Psychol. Med. 2014 44 15 3239 3248 10.1017/S0033291714000774 25066202
Lewandowski, K., Sperry, S., Cohen, B. & Öngür, D. Cognitive variability in psychotic disorders: A cross-diagnostic cluster analysis. Psychol. Med. 44(15), 3239–3248 (2014).25066202 10.1017/S0033291714000774
81. Reser MP Allott KA Killackey E Farhall J Cotton SM Exploring cognitive heterogeneity in first-episode psychosis: What cluster analysis can reveal Psychiatry Res. 2015 229 3 819 827 10.1016/j.psychres.2015.07.084 26272022
Reser, M. P., Allott, K. A., Killackey, E., Farhall, J. & Cotton, S. M. Exploring cognitive heterogeneity in first-episode psychosis: What cluster analysis can reveal. Psychiatry Res. 229(3), 819–827 (2015).26272022 10.1016/j.psychres.2015.07.084
82. Uren J Cotton SM Killackey E Saling MM Allott K Cognitive clusters in first-episode psychosis: Overlap with healthy controls and relationship to concurrent and prospective symptoms and functioning Neuropsychology 2017 31 7 787 10.1037/neu0000367 28368139
Uren, J., Cotton, S. M., Killackey, E., Saling, M. M. & Allott, K. Cognitive clusters in first-episode psychosis: Overlap with healthy controls and relationship to concurrent and prospective symptoms and functioning. Neuropsychology 31(7), 787 (2017).28368139 10.1037/neu0000367
83. Crouse JJ Moustafa AA Bogaty SE Hickie IB Hermens DF Parcellating cognitive heterogeneity in early psychosis-spectrum illnesses: A cluster analysis Schizophr. Res. 2018 202 91 98 10.1016/j.schres.2018.06.060 30042029
Crouse, J. J., Moustafa, A. A., Bogaty, S. E., Hickie, I. B. & Hermens, D. F. Parcellating cognitive heterogeneity in early psychosis-spectrum illnesses: A cluster analysis. Schizophr. Res. 202, 91–98 (2018).30042029 10.1016/j.schres.2018.06.060
84. Haining K Gajwani R Gross J Gumley AI Ince RA Lawrie SM Schultze-Lutter F Schwannauer M Uhlhaas PJ Characterising cognitive heterogeneity in individuals at clinical high-risk for psychosis: A cluster analysis with clinical and functional outcome prediction Eur. Arch. Psychiatry Clin. Neurosci. 2022 272 3 437 448 10.1007/s00406-021-01315-2 34401957
Haining, K. et al. Characterising cognitive heterogeneity in individuals at clinical high-risk for psychosis: A cluster analysis with clinical and functional outcome prediction. Eur. Arch. Psychiatry Clin. Neurosci. 272(3), 437–448 (2022).34401957 10.1007/s00406-021-01315-2
85. Tan EJ Rossell SL Subotnik KL Ventura J Nuechterlein KH Cognitive heterogeneity in first-episode psychosis and its relationship with premorbid developmental adjustment Psychol. Med. 2022 52 16 3885 3894 10.1017/S0033291721000738
Tan, E. J., Rossell, S. L., Subotnik, K. L., Ventura, J. & Nuechterlein, K. H. Cognitive heterogeneity in first-episode psychosis and its relationship with premorbid developmental adjustment. Psychol. Med. 52(16), 3885–3894 (2022).10.1017/S0033291721000738
86. Husa AP Moilanen J Murray GK Marttila R Haapea M Rannikko I Barnett JH Jones PB Isohanni M Remes AM Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort Psychiatry Res. 2017 247 130 138 10.1016/j.psychres.2016.10.085 27888683
Husa, A. P. et al. Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort. Psychiatry Res. 247, 130–138 (2017).27888683 10.1016/j.psychres.2016.10.085
87. Albert N Randers L Allott K Jensen HD Melau M Hjorthøj C Nordentoft M Cognitive functioning following discontinuation of antipsychotic medication. A naturalistic sub-group analysis from the OPUS II trial Psychol. Med. 2019 49 7 1138 1147 10.1017/S0033291718001836 30058511
Albert, N. et al. Cognitive functioning following discontinuation of antipsychotic medication. A naturalistic sub-group analysis from the OPUS II trial. Psychol. Med. 49(7), 1138–1147 (2019).30058511 10.1017/S0033291718001836
88. Joshi YB Thomas ML Braff DL Green MF Gur RC Gur RE Nuechterlein KH Stone WS Greenwood TA Lazzeroni LC Anticholinergic medication burden-associated cognitive impairment in schizophrenia Am. J. Psychiatry 2021 178 9 838 847 10.1176/appi.ajp.2020.20081212 33985348
Joshi, Y. B. et al. Anticholinergic medication burden-associated cognitive impairment in schizophrenia. Am. J. Psychiatry 178(9), 838–847 (2021).33985348 10.1176/appi.ajp.2020.20081212
89. Senner F Hiendl L Bengesser S Adorjan K Anghelescu I-G Baune BT Budde M Dannlowski U Dietrich DE Falkai P Medication adherence and cognitive performance in schizophrenia-spectrum and bipolar disorder: Results from the PsyCourse Study Transl. Psychiatry 2023 13 1 99 10.1038/s41398-023-02373-x 36966169
Senner, F. et al. Medication adherence and cognitive performance in schizophrenia-spectrum and bipolar disorder: Results from the PsyCourse Study. Transl. Psychiatry 13(1), 99 (2023).36966169 10.1038/s41398-023-02373-x
90. Gallardo-Ruiz R Crespo-Facorro B Setién-Suero E Tordesillas-Gutierrez D Long-term grey matter changes in first episode psychosis: A systematic review Psychiatry Investig. 2019 16 5 336 10.30773/pi.2019.02.10.1 31132837
Gallardo-Ruiz, R., Crespo-Facorro, B., Setién-Suero, E. & Tordesillas-Gutierrez, D. Long-term grey matter changes in first episode psychosis: A systematic review. Psychiatry Investig. 16(5), 336 (2019).31132837 10.30773/pi.2019.02.10.1
91. Vita A De Peri L Deste G Sacchetti E Progressive loss of cortical gray matter in schizophrenia: A meta-analysis and meta-regression of longitudinal MRI studies Transl. Psychiatry 2012 2 11 e190 e190 10.1038/tp.2012.116 23168990
Vita, A., De Peri, L., Deste, G. & Sacchetti, E. Progressive loss of cortical gray matter in schizophrenia: A meta-analysis and meta-regression of longitudinal MRI studies. Transl. Psychiatry 2(11), e190–e190 (2012).23168990 10.1038/tp.2012.116
92. Fusar-Poli P Smieskova R Serafini G Politi P Borgwardt S Neuroanatomical markers of genetic liability to psychosis and first episode psychosis: A voxelwise meta-analytical comparison World J. Biol. Psychiatry 2014 15 3 219 228 10.3109/15622975.2011.630408 22283467
Fusar-Poli, P., Smieskova, R., Serafini, G., Politi, P. & Borgwardt, S. Neuroanatomical markers of genetic liability to psychosis and first episode psychosis: A voxelwise meta-analytical comparison. World J. Biol. Psychiatry 15(3), 219–228 (2014).22283467 10.3109/15622975.2011.630408
93. Iwabuchi S Liddle PF Palaniyappan L Clinical utility of machine-learning approaches in schizophrenia: Improving diagnostic confidence for translational neuroimaging Front. Psych. 2013 4 95
Iwabuchi, S., Liddle, P. F. & Palaniyappan, L. Clinical utility of machine-learning approaches in schizophrenia: Improving diagnostic confidence for translational neuroimaging. Front. Psych. 4, 95 (2013).
94. Schnack HG Nieuwenhuis M van Haren NE Abramovic L Scheewe TW Brouwer RM Pol HEH Kahn RS Can structural MRI aid in clinical classification? A machine learning study in two independent samples of patients with schizophrenia, bipolar disorder and healthy subjects Neuroimage 2014 84 299 306 10.1016/j.neuroimage.2013.08.053 24004694
Schnack, H. G. et al. Can structural MRI aid in clinical classification? A machine learning study in two independent samples of patients with schizophrenia, bipolar disorder and healthy subjects. Neuroimage 84, 299–306 (2014).24004694 10.1016/j.neuroimage.2013.08.053
95. Vieira S Gong Q-Y Pinaya WH Scarpazza C Tognin S Crespo-Facorro B Tordesillas-Gutierrez D Ortiz-García V Setien-Suero E Scheepers FE Using machine learning and structural neuroimaging to detect first episode psychosis: Reconsidering the evidence Schizophr. Bull. 2020 46 1 17 26 10.1093/schbul/sby189 30809667
Vieira, S. et al. Using machine learning and structural neuroimaging to detect first episode psychosis: Reconsidering the evidence. Schizophr. Bull. 46(1), 17–26 (2020).30809667 10.1093/schbul/sby189
96. Dempster K Norman R Théberge J Densmore M Schaefer B Williamson P Cognitive performance is associated with gray matter decline in first-episode psychosis Psychiatry Res. Neuroimaging 2017 264 46 51 10.1016/j.pscychresns.2017.04.007 28458083
Dempster, K. et al. Cognitive performance is associated with gray matter decline in first-episode psychosis. Psychiatry Res. Neuroimaging 264, 46–51 (2017).28458083 10.1016/j.pscychresns.2017.04.007
97. Ivleva EI Bidesi AS Keshavan MS Pearlson GD Meda SA Dodig D Moates AF Lu H Francis AN Tandon N Gray matter volume as an intermediate phenotype for psychosis: Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) Am. J. Psychiatry 2013 170 11 1285 1296 10.1176/appi.ajp.2013.13010126 24185241
Ivleva, E. I. et al. Gray matter volume as an intermediate phenotype for psychosis: Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am. J. Psychiatry 170(11), 1285–1296 (2013).24185241 10.1176/appi.ajp.2013.13010126
98. Liu N Xiao Y Zhang W Tang B Zeng J Hu N Chandan S Gong Q Lui S Characteristics of gray matter alterations in never-treated and treated chronic schizophrenia patients Transl. Psychiatry 2020 10 1 136 10.1038/s41398-020-0828-4 32398765
Liu, N. et al. Characteristics of gray matter alterations in never-treated and treated chronic schizophrenia patients. Transl. Psychiatry 10(1), 136 (2020).32398765 10.1038/s41398-020-0828-4
99. Glahn DC Laird AR Ellison-Wright I Thelen SM Robinson JL Lancaster JL Bullmore E Fox PT Meta-analysis of gray matter anomalies in schizophrenia: Application of anatomic likelihood estimation and network analysis Biol. Psychiat. 2008 64 9 774 781 10.1016/j.biopsych.2008.03.031 18486104
Glahn, D. C. et al. Meta-analysis of gray matter anomalies in schizophrenia: Application of anatomic likelihood estimation and network analysis. Biol. Psychiat. 64(9), 774–781 (2008).18486104 10.1016/j.biopsych.2008.03.031
100. Shan X-X Ou Y-P Pan P Ding Y-D Zhao J Liu F Chen J-D Guo W-B Zhao J-P Increased frontal gray matter volume in individuals with prodromal psychosis CNS Neurosci. Ther. 2019 25 9 987 994 10.1111/cns.13143 31129924
Shan, X.-X. et al. Increased frontal gray matter volume in individuals with prodromal psychosis. CNS Neurosci. Ther. 25(9), 987–994 (2019).31129924 10.1111/cns.13143
101. Haijma SV Van Haren N Cahn W Koolschijn PCM Hulshoff Pol HE Kahn RS Brain volumes in schizophrenia: A meta-analysis in over 18 000 subjects Schizophr. Bull. 2013 39 5 1129 1138 10.1093/schbul/sbs118 23042112
Haijma, S. V. et al. Brain volumes in schizophrenia: A meta-analysis in over 18 000 subjects. Schizophr. Bull. 39(5), 1129–1138 (2013).23042112 10.1093/schbul/sbs118
102. Woodward ND Heckers S Brain structure in neuropsychologically defined subgroups of schizophrenia and psychotic bipolar disorder Schizophr. Bull. 2015 41 6 1349 1359 10.1093/schbul/sbv048 25904725
Woodward, N. D. & Heckers, S. Brain structure in neuropsychologically defined subgroups of schizophrenia and psychotic bipolar disorder. Schizophr. Bull. 41(6), 1349–1359 (2015).25904725 10.1093/schbul/sbv048
103. Wenzel J Haas SS Dwyer DB Ruef A Oeztuerk OF Antonucci LA von Saldern S Bonivento C Garzitto M Ferro A Cognitive subtypes in recent onset psychosis: Distinct neurobiological fingerprints? Neuropsychopharmacology 2021 46 8 1475 1483 10.1038/s41386-021-00963-1 33723384
Wenzel, J. et al. Cognitive subtypes in recent onset psychosis: Distinct neurobiological fingerprints?. Neuropsychopharmacology 46(8), 1475–1483 (2021).33723384 10.1038/s41386-021-00963-1
104. Koutsouleris N Patschurek-Kliche K Scheuerecker J Decker P Bottlender R Schmitt G Rujescu D Giegling I Gaser C Reiser M Neuroanatomical correlates of executive dysfunction in the at-risk mental state for psychosis Schizophr. Res. 2010 123 2-3 160 174 10.1016/j.schres.2010.08.026 20826078
Koutsouleris, N. et al. Neuroanatomical correlates of executive dysfunction in the at-risk mental state for psychosis. Schizophr. Res. 123(2–3), 160–174 (2010).20826078 10.1016/j.schres.2010.08.026
105. Gould IC Shepherd AM Laurens KR Cairns MJ Carr VJ Green MJ Multivariate neuroanatomical classification of cognitive subtypes in schizophrenia: A support vector machine learning approach NeuroImage Clin. 2014 6 229 236 10.1016/j.nicl.2014.09.009 25379435
Gould, I. C. et al. Multivariate neuroanatomical classification of cognitive subtypes in schizophrenia: A support vector machine learning approach. NeuroImage Clin. 6, 229–236 (2014).25379435 10.1016/j.nicl.2014.09.009
106. Rapado-Castro M Villar-Arenzana M Janssen J Fraguas D Bombin I Castro-Fornieles J Mayoral M González-Pinto A de la Serna E Parellada M Fronto-parietal gray matter volume loss is associated with decreased working memory performance in adolescents with a first episode of psychosis J. Clin. Med. 2021 10 17 3929 10.3390/jcm10173929 34501377
Rapado-Castro, M. et al. Fronto-parietal gray matter volume loss is associated with decreased working memory performance in adolescents with a first episode of psychosis. J. Clin. Med. 10(17), 3929 (2021).34501377 10.3390/jcm10173929
107. Picó-Pérez M Vieira R Fernández-Rodríguez M De Barros MAP Radua J Morgado P Multimodal meta-analysis of structural gray matter, neurocognitive and social cognitive fMRI findings in schizophrenia patients Psychol. Med. 2022 52 4 614 624 10.1017/S0033291721005523 35129109
Picó-Pérez, M. et al. Multimodal meta-analysis of structural gray matter, neurocognitive and social cognitive fMRI findings in schizophrenia patients. Psychol. Med. 52(4), 614–624 (2022).35129109 10.1017/S0033291721005523
108. Wolf RC Höse A Frasch K Walter H Vasic N Volumetric abnormalities associated with cognitive deficits in patients with schizophrenia Eur. Psychiatry 2008 23 8 541 548 10.1016/j.eurpsy.2008.02.002 18434103
Wolf, R. C., Höse, A., Frasch, K., Walter, H. & Vasic, N. Volumetric abnormalities associated with cognitive deficits in patients with schizophrenia. Eur. Psychiatry 23(8), 541–548 (2008).18434103 10.1016/j.eurpsy.2008.02.002
109. Zhu Y Womer FY Leng H Chang M Yin Z Wei Y Zhou Q Fu S Deng X Lv J The relationship between cognitive dysfunction and symptom dimensions across schizophrenia, bipolar disorder, and major depressive disorder Front. Psych. 2019 10 253 10.3389/fpsyt.2019.00253
Zhu, Y. et al. The relationship between cognitive dysfunction and symptom dimensions across schizophrenia, bipolar disorder, and major depressive disorder. Front. Psych. 10, 253 (2019).10.3389/fpsyt.2019.00253
110. Palaniyappan L Balain V Liddle PF The neuroanatomy of psychotic diathesis: A meta-analytic review J. Psychiatr. Res. 2012 46 10 1249 1256 10.1016/j.jpsychires.2012.06.007 22790253
Palaniyappan, L., Balain, V. & Liddle, P. F. The neuroanatomy of psychotic diathesis: A meta-analytic review. J. Psychiatr. Res. 46(10), 1249–1256. 10.1016/j.jpsychires.2012.06.007 (2012).22790253 10.1016/j.jpsychires.2012.06.007
111. Carbon M Correll CU Thinking and acting beyond the positive: The role of the cognitive and negative symptoms in schizophrenia CNS Spectr. 2014 19 S1 35 53 10.1017/S1092852914000601
Carbon, M. & Correll, C. U. Thinking and acting beyond the positive: The role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 19(S1), 35–53. 10.1017/S1092852914000601 (2014).10.1017/S1092852914000601
112. Oomen, P. P. et al. Longitudinal clinical and functional outcome in distinct cognitive subgroups of first-episode psychosis: A cluster analysis. Psychol. Med. (2021).
113. Kas MJ Penninx B Sommer B Serretti A Arango C Marston H A quantitative approach to neuropsychiatry: The why and the how Neurosci. Biobehav. Rev. 2019 97 3 9 10.1016/j.neubiorev.2017.12.008 29246661
Kas, M. J. et al. A quantitative approach to neuropsychiatry: The why and the how. Neurosci. Biobehav. Rev. 97, 3–9. 10.1016/j.neubiorev.2017.12.008 (2019).29246661 10.1016/j.neubiorev.2017.12.008
114. Hitchcock PF Fried EI Frank MJ Computational psychiatry needs time and context Annu. Rev. Psychol. 2022 73 243 10.1146/annurev-psych-021621-124910 34579545
Hitchcock, P. F., Fried, E. I. & Frank, M. J. Computational psychiatry needs time and context. Annu. Rev. Psychol. 73, 243 (2022).34579545 10.1146/annurev-psych-021621-124910
115. Hartigan JA Wong MA A K-means clustering algorithm J. R. Stat. Soc. Ser. C (Appl. Stat.) 1979 28 1 100 108 10.2307/2346830
Hartigan, J. A. & Wong, M. A. A K-means clustering algorithm. J. R. Stat. Soc. Ser. C (Appl. Stat.) 28(1), 100–108. 10.2307/2346830 (1979).10.2307/2346830
116. Ertöz L Steinbach M Kumar V Finding clusters of different sizes, shapes, and densities in noisy, high dimensional data Proceed. Soc. Ind. Appl. Math. (SIAM) 2003 10.1137/1.9781611972733.5
Ertöz, L., Steinbach, M. & Kumar, V. Finding clusters of different sizes, shapes, and densities in noisy, high dimensional data. Proceed. Soc. Ind. Appl. Math. (SIAM)[SPACE]10.1137/1.9781611972733.5 (2003).10.1137/1.9781611972733.5
117. Huys QJ Maia TV Frank MJ Computational psychiatry as a bridge from neuroscience to clinical applications Nat. Neurosci. 2016 19 3 404 413 10.1038/nn.4238 26906507
Huys, Q. J., Maia, T. V. & Frank, M. J. Computational psychiatry as a bridge from neuroscience to clinical applications. Nat. Neurosci. 19(3), 404–413 (2016).26906507 10.1038/nn.4238
118. Mkrtchian, A. , Valton, V., Roiser, J. P. Reliability of decision-making and reinforcement learning computational parameters. bioRxiv (2021). 10.1101/2021.06.30.450026. eprint: https://www.biorxiv.org/content/early/2021/11/06/2021.06.30.450026.full.pdf.
